Masataka Taguchi
Nagasaki, Japan
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 28 publications
Comparison of clinical characteristics and cytogenetic abnormalities between myelodysplastic syndromes in Nagasaki atomic bomb survivors and therapy-related myelodysplastic syndromes
Journal: [Rinsho ketsueki] The Japanese journal of clinical hematology
Published: August 30, 2026
Clonal hematopoiesis related to ionizing radiation in atomic bomb survivors.
Journal: Leukemia
Published: May 12, 2026
Improvement in survival of patients with higher risk but not lower risk myelodysplastic syndromes over 20 years: A retrospective study from Nagasaki, Japan.
Journal: British journal of haematology
Published: September 30, 2025
Efficacy of Azacitidine Plus Venetoclax in Acute Myeloid Leukemia Transformed from Myelodysplastic Syndrome after Failure of Azacitidine Monotherapy.
Journal: Internal medicine (Tokyo, Japan)
Published: July 09, 2025
Comprehensive analysis of serum immune complexes identifies chronic graft-versus-host disease-associated antigenic molecules: A study by the Nagasaki transplant group.
Journal: Human immunology
Published: May 17, 2025
RUNX1 expression is regulated by a super-enhancer and is a therapeutic target in adult T-cell leukemia/lymphoma.
Journal: Leukemia & lymphoma
Published: September 02, 2024
Improved survival among elderly patients with aggressive adult T-cell leukemia/lymphoma: Impact of mogamulizumab-containing chemotherapy.
Journal: International journal of hematology
Published: February 06, 2024
JMJD3-mediated senescence is required to overcome stress-induced hematopoietic defects.
Journal: EMBO reports
Published: November 16, 2023
Postazacitidine clone size predicts long-term outcome of patients with myelodysplastic syndromes and related myeloid neoplasms.
Journal: Blood advances
Published: December 19, 2022
Clinical features of non-infectious pulmonary complications after donor lymphocyte infusion in post-transplant patients: The Nagasaki Transplant Group Experience.
Journal: Transplant immunology
Published: June 11, 2022
Efficacy and Cardiovascular Adverse Events of Long-term Treatment with Tyrosine Kinase Inhibitors for Chronic Myeloid Leukemia: A Report from the Nagasaki CML Study Group.
Journal: Internal medicine (Tokyo, Japan)
Published: February 22, 2021
Last Updated: 09/26/2026